# Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With

Source: https://onco.cc/trials/nct05607550/  
OnCo record `nct05607550` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Furmonertinib in non-small-cell lung cancer and small-cell lung cancer, run by ArriVent BioPharma, Inc., active and no longer recruiting.

## Summary

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) is a phase 3 interventional study registered as NCT05607550 by ArriVent BioPharma, Inc., with 398 participants enrolled, started 2023-06-01 and due to reach its primary completion in 2025-08-15. Interventions recorded: furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy. Conditions listed: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05607550
- Phase: 3
- Setting: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
- Sponsor: ArriVent BioPharma, Inc.
- Enrolled: 398

## Sources

- ClinicalTrials.gov NCT05607550: https://clinicaltrials.gov/study/NCT05607550

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Furmonertinib](https://onco.cc/drugs/furmonertinib/)
- companies: [ArriVent BioPharma](https://onco.cc/companies/arrivent/)

---
JSON: https://onco.cc/api/v1/entities/nct05607550.json